Title: New approaches for treatment of lung cancer 
References: RTC-2017-6576-1 
Start date: 6/1/2018 
End date: 6/30/2021 
Funding Source: Global project budget. The CHALLENGES-COLLABORATION program is co-financed by the European Regional Development Fund (ERDF)

Summary:

The project proposed is aimed ultimately at the development “New approaches for treatment of lung cancer”. Lung cancer continues to be a main cause of mortality and is associated to a great extent to smoking of tobacco that acts as a carcinogen. To date there are no animal models of lung cancer induced by tobacco and animal models for lung cancer differ significantly form the reality found in the clinic. The project proses the complex task of developing animal models of lung cancer induced by the same inducing agent as in humans, that is tobacco smoke, and with a molecular biology and histology as close as possible to that found in smoking lung cancer patients. Project will take advantage of these animal models for a better understanding of the disease and evaluation of drugs reformulated for administration via inhalation. The project includes necessary participation of the Experimental Oncology Group at the Centro Nacional de Investigaciones Oncológicas lead by Dr Mariano Barbacid, as world expert in the molecular biology of lung cancer and induction of altered genotypes with mutations usually found in lung cancer patients. The CNIO will develop mice with conditional mutations in the tumor suppressor genes Rb1 and Tp53 commonly found mutated in small cell lung cancer (SCLC) in humans. Presence of these mutations is not sufficient to establish a meaningful animal model of lung cancer so project proposes to expose these mutated animals to tobacco smoke as a secondary inducer of the disease. The correct administration of tobacco smoke requires appropriate technology that doses animals with same exposure times with standard smoke in a controlled and reproducible way. The Science to Business Foundation (FS2B) has the capacity and experience to develop and put into practice the necessary equipment and the necessary analytical protocols to quantify the administered smoke. The FS2B will also take on the role of formulating conventional and other drugs that may be in development for their administration by inhalation or other routes. The FS2B will also take on the role of scientific coordinator Vivotecnia Research S.L (VVR) is an established company with ample experience in in vivo toxicology studies and evaluation of the consequences of exposing different animal species to toxic agents such as tobacco. VVR has experience in managing scientific projects in a Good Laboratory Practices (GLP) setting and has the capacity to lead the project and maximize the return on the obtain results from a scientific, business and contribution to human health. VVR will take on the important task of managing the animals, evolution and development of lung cancer and histopathologic evaluation of the mutated animals before and after exposure to tobacco smoke and before and after treatment with different drugs.